Form Type: 4

SEC EDGAR Link
Accession Number:0001567619-22-001462
Date:2022-01-19
Issuer: SENSEI BIOTHERAPEUTICS, INC. (SNSE)
Original Submission Date:

Reporting Person:

CAMBRIAN BIOPHARMA INC
19 MORRIS AVENUE
BROOKLYN NAVY YARD, BUILDING 128 BROOKLYN, NY 11205

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2022-01-19 P 10,244 a $4.97 4,995,876 f2 direct
COMMON STOCK 2022-01-20 P 20,000 a $5.17 5,015,876 f2 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 the price reported is a weighted average price. these shares were purchased in multiple transactions at prices ranging from $4.90 to $5.00, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.
f2 these shares are held by cambrian biopharma inc, a delaware corporation ("cambrian"). the chief executive officer of cambrian, james peyer, may direct the voting and disposition of the shares held by cambrian, subject in certain instances to the approval of cambrian's board of directors. mr. peyer disclaims beneficial ownership of such shares.
f3 the price reported is a weighted average price. these shares were purchased in multiple transactions at prices ranging from $5.10 to $5.25, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.
WhaleWisdom Logo

Elevate your investments